Program
rilvegostomig
Also written as “Rilvegostomig”, “AZD2936” and “AZD9592 + Rilvegostomig”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Biliary Tract Neoplasms · Carcinoma, Hepatocellular · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.
Drug pageRilvegostomig: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 2222 open or running | phase 3since Oct 26, 2023 | Dec 13, 2018 | May 4, 2027phase 2 · NCT04379596 |
| Presage Biosciences | 21 open or running | early phase 1since Sep 1, 2020 | Sep 1, 2020 | Dec 2031early phase 1 · NCT04541108 |
- Named in AstraZeneca’s own pipeline as
rilvegostomig
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Daiichi Sankyo and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Presage Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Sep 1, 2020First study: early phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT04541108 · 15 enrolled · United States
- Jul 21, 2022Named rilvegostomigINNProposed as its International Nonproprietary Name in WHO's List 127 · before, AZD2936
- Apr 3, 2024Early phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT06366451 · 17 enrolled · United States
Ahead
- Dec 2031Primary completion: early phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT04541108
TargetBeta
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory …”NCIt, read by Claude
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory mot”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
Studies
All 2 Presage Biosciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06366451Squamous Cell Carcinoma of Head and Neck · United States | Early 1 | Completed | Mar 25, 2026 | 17 |
| NCT04541108Squamous Cell Carcinoma of Head and Neck · United States | Early 1 | Active, not recruiting | Dec 2031 | 15 |
How it is read
Names in the registry
- “Rilvegostomig”, 20 entries
- “AZD2936”, 2 entries
- “AZD9592 + Rilvegostomig”, 2 entries
- “AZD8205 and AZD2936 (Rilvegostomig)”, 1 entry
- “AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 9 studies
- Stomach Neoplasms, 4 studies
- Biliary Tract Neoplasms, 3 studies
- Carcinoma, Hepatocellular, 2 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.